Our Pipeline

---

 ViroCarb has developed a brand-new proprietary class of antiviral drug candidates in collaboration with leading academics from various Canadian Universities, the result of over 12 years of research. Our approach is to exploit the dependency of viruses on their host by altering their ability to use a host cell process involved in viral RNA processing. The rapid evolution of viruses leads to resistance to current drugs targeting viral components; our host-directed approach impedes the replication of multiple viruses without producing drug resistance since viral changes don’t affect the sensitivity to our drugs. Our drug candidates exhibit potent antiviral activity against multiple viruses, including coronavirus and influenza virus, with enhanced efficacy and safety compared with first-line treatments for COVID-19 and flu and lack of drug resistance development. Our pan-antiviral drug candidate could become an effective oral treatment of the main respiratory viral infections.